Perseus Proteomics Inc. Logo

Perseus Proteomics Inc.

Develops antibody drugs for cancer, provides research support, and sells diagnostic reagents.

4882 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
目黒区駒場四丁目7番6号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Perseus Proteomics Inc. is a drug discovery biotechnology company founded in 2001 as a venture from the University of Tokyo. The company focuses on creating novel antibody-based therapeutics to treat cancer and other diseases, utilizing its proprietary and unique antibody technologies. Its business operations are structured around three core segments: Drug Discovery, which develops its pipeline of potential antibody drugs; Antibody Research Support Services for partner institutions; and the direct sale of antibody products and diagnostic reagents, such as ELISA kits. The company's mission is to contribute to global healthcare by developing innovative treatments for people suffering from diseases worldwide.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Perseus Proteomics Inc. and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-06-27 09:28
Post-Annual General Meeting Information
臨時報告書
Japanese 25.9 KB
2025-06-27 08:34
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 08:33
Regulatory News Service
訂正有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 1.5 MB
2025-06-27 08:33
Registration Form
確認書
Japanese 8.2 KB
2025-06-27 08:32
Regulatory News Service
訂正有価証券報告書-第23期(2022/04/01-2023/03/31)
Japanese 1.5 MB
2025-06-27 08:32
Regulatory News Service
内部統制報告書-第25期(2024/04/01-2025/03/31)
Japanese 22.4 KB
2025-06-27 08:31
Regulatory News Service
確認書
Japanese 8.1 KB
2025-06-27 08:31
Annual Report
有価証券報告書-第25期(2024/04/01-2025/03/31)
Japanese 2.6 MB
2025-05-21 08:31
Regulatory News Service
臨時報告書
Japanese 20.2 KB
2024-11-14 07:34
Report Publication Announcement
確認書
Japanese 8.1 KB
2024-11-14 07:34
Interim Report
半期報告書-第25期(2024/04/01-2025/03/31)
Japanese 163.4 KB
2024-06-20 07:40
Post-Annual General Meeting Information
臨時報告書
Japanese 23.6 KB
2024-06-20 07:34
Governance Information
内部統制報告書-第24期(2023/04/01-2024/03/31)
Japanese 21.2 KB
2024-06-20 07:34
Registration Form
確認書
Japanese 8.1 KB
2024-06-20 07:33
Annual Report
有価証券報告書-第24期(2023/04/01-2024/03/31)
Japanese 2.8 MB

Automate Your Workflow. Get a real-time feed of all Perseus Proteomics Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Perseus Proteomics Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
SoftOx Solutions AS Logo
Develops non-toxic, AMR-safe antimicrobials for wound care, disinfection & airway infections.
Norway SOFTX
Solasia Pharma K.K. Logo
In-licenses and commercializes oncology treatments and supportive care products in Asia.
Japan 4597
Sopharma AD Logo
Develops, manufactures, and distributes pharmaceuticals and generics in Bulgaria and regional markets.
Bulgaria SFA
Spago Nanomedical AB Logo
Developing nanomedicines for precise cancer diagnosis and targeted radionuclide therapy.
Sweden SPAGO
Spexis AG Logo
Clinical-stage biopharma developing macrocyclic therapeutics for rare diseases and oncology.
Switzerland SPEX
Sprint Bioscience Logo
Develops & out-licenses preclinical oncology drugs for difficult-to-treat cancers.
Sweden SPRINT
STADA Arzneimittel AG Logo
A leading European manufacturer of generics, consumer healthcare, and specialty pharmaceuticals.
Germany SAZ
Stayble Therapeutics AB Logo
Develops an injectable drug for lumbar disc herniation pain as an alternative to surgery.
Sweden STABL
STCUBE Logo
Develops first-in-class immunotherapies targeting BTN1A1 for treatment-resistant cancers.
South Korea 052020
STELLA PHARMA CORPORATION Logo
Develops boron drugs for Boron Neutron Capture Therapy (BNCT), a targeted cancer radiation treatment.
Japan 4888

Talk to a Data Expert

Have a question? We'll get back to you promptly.